MADRID, 24 (EUROPA PRESS)<\/p>\n
Lilly has presented the results of three clinical trials in phase III on the dulaglutida drug, an analogue of long-acting GLP-1 and under investigation, that demonstrate its effectiveness as a weekly treatment against diabetes type 2.<\/p>\n
in three studies (AWARD-1, AWARD-3 and AWARD-5) reached the main objectives of efficiency, measured by the reduction in hemoglobin A1c (HbA1c) with a dose of 1.5 milligrams.<\/p>\n
following these primary objectives, examined its superiority in reducing HbA1c and studied two doses of dulaglutida (0, 75 mg and 1, 5 mg) demonstrated a reduction in statistically higher in the baseline HbA1c compared the following drugs: Exenatide injection twice a day for 26 weeks (AWARD-1), metformin for 26 weeks (AWARD-3), and sitagliptin for 52 weeks (AWARD-5).<\/p>\n
< pF\u00fcr Zwischenf\u00e4lle, die h\u00e4ufigsten wurden gastrointestinale in der Natur, mit fr\u00fcheren Studien mit Dulaglutida.<\/p>\n
dar\u00fcber hinaus derzeit durchgef\u00fchrt wird in zwei anderen Studien das Molek\u00fcl LY2189265 zur Behandlung von Diabetes, beurteilen die schlie\u00dfen, wird in den n\u00e4chsten paar Monate.<\/p>\n
“Wir werden aufgefordert, mit den Ergebnissen, die bisher durch unsere Studien in Phase III der Dulaglutida gewonnen und wir freuen uns, Ihnen ein wenig n\u00e4her zu bieten eine neue Behandlungsoption f\u00fcr GLP-1 f\u00fcr Diabetes Typ 2, k\u00f6nnen”, sagte Enrique Conterno, Pr\u00e4sident von Lilly Diabetes.<\/p>\n
Lilly beabsichtigt, detaillierte Daten von Studien AWARD an Fachtagungen in 2013 und 2014 vorzulegen. Das Unternehmen erwartet, Dulaglutida Daten an Aufsichtsbeh\u00f6rden w\u00e4hrend 2013 mit den Fristen f\u00fcr die Registrierung in den Vereinigten Staaten bis zum erfolgreichen Abschluss der gesetzlichen Anforderungen der amerikanischen Drug Agency (FDA) f\u00fcr die Bewertung des kardiovaskul\u00e4ren Risikos zu senden. <\/p>\n","protected":false},"excerpt":{"rendered":"
MADRID, 24 (EUROPA PRESS) Lilly has presented the results of three clinical trials in phase III on the dulaglutida drug, an analogue of long-acting GLP-1 and under investigation, that demonstrate its effectiveness as a weekly treatment against diabetes type 2. in three studies (AWARD-1, AWARD-3 and AWARD-5) reached the main objectives of efficiency, measured by […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-27862","post","type-post","status-publish","format-standard","hentry","category-allgemeine","et-doesnt-have-format-content","et_post_format-et-post-format-standard"],"_links":{"self":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts\/27862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/comments?post=27862"}],"version-history":[{"count":0,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts\/27862\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/media?parent=27862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/categories?post=27862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/tags?post=27862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}